News

Review Dermatology Times' coverage of Rosacea Awareness Month.

Dermatology Times is looking back on the top stories in dermatology from the month of April.

A decision from the FDA is expected in the second half of 2024.

Dermatology Times is recapping our top expert interviews from the month of April.

López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.

A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.

A study found that in addition, recovery time was both quick and yielded minimal symptoms.

The FDA’s PDUFA date is expected in quarter 4 of 2024.

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including the appointment of All Detergent's first chief dermatology advisor, Incyte's acquisition of Escient Pharmaceuticals, and more.

ICYMI, this week we had news about a study of upadacitinib versus dupilumab in atopic dermatitis, the European Union's approval of bimekizumab for HS, and more.

Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.

Study findings suggest OCT's effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements.

Skin cancer risk classification lacks reliability for darker skin tones and fails in evaluating cutaneous medical conditions or cosmetic interventions, according to creators of the scale.

Earlier this week, we shared our third Rosacea Awareness Month quiz. Review the answers and your responses below.

A recent survey covered topics including skin-aging prevention, care-seeking behavior, trust in professionals, and more.

A cross-sectional study revealed an increase and heightened prevalence of Demodex and demodicosis in individuals with psoriasis receiving biologic therapy.

In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.

Researchers conducted a population-based study examining a sample of patients with HS during hospital admissions.

Desai emphasized that most dermatologists would rather biopsy a potential melanoma than miss one that could become deadly.

In online discussion April 23, commissioners cited health care specifically among their reasons for supporting the ban.

A review found that Mohs micrographic surgery and conventional excision yielded comparable patient reported outcomes.

At present, deployed members of the military are not permitted to be receiving therapy with systemic therapies such as immunomodulators and biologics.

Posters from the Academy of Managed Care Pharmacy annual meeting featured studies on atopic dermatitis.

Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.

Chinese clinical researchers recently presented a unique case of JLIS manifesting as erythematous papules and infiltrative plaques on the nose and upper jaw, resembling rosacea.

In vitro studies demonstrated that retinoic acid aids stem cells in transitioning away from a state of flexibility in wound healing.

The CRL indicates that the timing proposed for data submission would not allow enough time for the FDA to complete its review by the May 25 PDUFA date.

LC-OCT provided quick, noninvasive assessment of skin conditions with detailed imaging aids diagnosis and treatment, especially for patients with darker skin types.

Hasbargen presented Mohs surgery pearls on closure types and pattern recognition at the 2024 Diversity in Dermatology meeting.